Rare Cancer Webinar Series
The National Cancer Institute defines a rare cancer as one that occurs in fewer than 15 out of 100,000 people per year; however, when taken together, rare cancers account for approximately 25% of all cancer cases that are diagnosed each year in the United States. Rare cancers are often associated with poorer outcomes, and large disparities in incidence and mortality rates for certain types have been documented, particularly in terms of race. Examples of rare cancers include: ovarian, pancreatic, esophageal, multiple myeloma, liver, and stomach.
There are numerous challenges to studying rare cancers, and, because of these challenges, there are large gaps in knowledge related to the prevention, diagnosis, and treatment of many types of rare cancers. Thus, the purpose of this webinar series is twofold:
- to highlight work being done to investigate various aspects of rare cancers, including studies on etiology, risk, prognosis, and survivorship; and,
- to better understand the challenges, and strategies to overcome these challenges, related to studying rare cancers.
Any interested individual is invited to participate. The webinars are free, but require pre-registration. Each webinar will be 60 to 90 minutes in length and includes a presentation followed by discussion moderated by EGRP staff. Instructions for connecting to the webinars will be sent via email to those individuals who register.
Upcoming Topics and Speakers
May 2, 2019 2:00 p.m. to 3:00 p.m. ET
LiFE – An International Consortium Approach to Researching a Rare Cancer Syndrome
Jeffrey Weitzel, MD
Chief, Division of Clinical Cancer Genomics, City of Hope
Sharon Sand, CCRP
Clinical Research Administrator, City of Hope
Li-Fraumeni Exploration (LiFE) is the consortium studying Li-Fraumeni Syndrome and carriers of TP53 variants. This webinar will describe the steps taken to form the consortium, and the subsequent process of assembling data from multiple participating centers at the LiFE Data Coordinating Center (DCC). The DCC investigator and the DCC administrator will present work to date, challenges, successes, outcomes, and practical tips from running and housing the DCC, including transfer of data, defining critical data points and then expanding the data dictionary, managing data transfer agreements, working closely with an advocacy organization, and facilitating data requests. The LiFE Consortium is led by a steering committee of key thought leaders of Li-Fraumeni Syndrome, and includes data from seven participating sites and nearly 1,000 pedigrees with multiple affected cases with cancer history and genetic status.
Past Topics and Speakers
December 6, 2018 2:00 p.m. to 3:30 p.m. ET
Recruitment Strategies for Rare Cancer Research Studies
Michael Grever, M.D.
Oncologist and Faculty Emeritus, Ohio State University
Corrie Painter, Ph.D.
Associate Director, Operations and Scientific Outreach, Cancer Program at the Broad Institute at MIT
Joellen Schildkraut, Ph.D.
Professor, Department of Public Health Sciences, University of Virginia School of Medicine
This webinar described different strategies that have been successfully used by investigators to recruit individuals diagnosed with rare or understudied cancers into research studies. Three investigators presented their experiences in studying rare cancers, including their methods of recruiting and maintaining patient/participant engagement.
Watch the archived video for this webinar.
September 25, 2018 2:00 p.m. to 3:00 p.m. ET
Micro-RNA Genetic Variation Related to Head and Neck Cancer Risk and Survival
Brock Christensen, Ph.D.
Associate Professor of Epidemiology, Community and Family Medicine, and Molecular and Systems Biology, Dartmouth Geisel School of Medicine
Polymorphisms in microRNAs and their target sites can disrupt microRNA-dependent gene regulation, and have been associated with cancer susceptibility and outcomes. However, genome-scale analyses of genetic variation related to micro-RNA (miR-SNPs) in cancer are lacking and microRNA-related SNPs tend to be in poor linkage with markers genotyped with many platforms used in GWAS approaches. This presentation included results from testing the relation of >40,000 common miR-SNPs with head and neck risk and survival in two independent studies with more than 2,000 total cases and more than 2,000 total controls. In addition, approaches for and results from investigating the functional implications of miR-SNPs on miRNA-mRNA interactions were discussed.
Questions about individual webinars, or the series, may be submitted via e-mail to Lisa Gallicchio, Ph.D., Program Director, Clinical and Translational Epidemiology Branch, Epidemiology and Genomics Research Program.